Kornimate/medical-research-clean huggingface dataset:
efficacy of a structured, dimension-based, sti in de-compensated personality-disorder, hospitalized, patients

Conditions: Personality Disorders

Summary: the assessment of the efficacy of a structured, dimension-based, sti (short term intervention) in de-compensated personality-disorder, hospitalized, patients

the current study attempts to design a short-term intervention aimed at stabilizing decompensate personality disorder patients in hospitalization. the study is structured as a pilot study, thus will enroll 20 patients only. patients, upon being hospitalized and after signing the consent to participate in the study, will be randomized to two groups: the first will be treated by the novel, loop, concept' the other will be tau, as routinely done with persdis patients in the investigators facility. the outcome parameters will be changes in series of questionnaires filled upon being enrolled and at the end of the intervention. another outcome parameter will be readmission rates in the post-intervention period (3 months). the loop conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the "place" where the investigators experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). the loop intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes.

Eligibility criteria:
inclusion criteria: * cluster 2 diagnosis * no suicide attemts 1 month prior to admission * regularly treated * an active support system * no urgent need for rx changes exclusion criteria: * drug abuse * an active axis 1 diagnosis that requires change in rx * unable to read/write fluently
early identification of malignant brain edema in large artery occlusive stroke after endovascular therapy (embrace study)

Conditions: Endovascular Therapy; Brain Edema; Prediction Model; Ischemic Stroke

Summary: to design and validate a predictive model for malignant brain edema after endovascular thrombectomy.

stroke is a significant global cause of death and disability. endovascular thrombectomy (evt) is currently the best treatment for acute large vessel occlusion stroke (alvos), as it can greatly reduce mortality and improve patient outcomes. however, only half of patients who undergo evt achieve functional independence, and malignant brain edema (mbe), a severe complication, can occur after the procedure, leading to a poor prognosis. previous studies have confirmed the effectiveness of early decompressive hemicraniectomy in reducing morbidity and mortality in patients with malignant brain edema. therefore, identifying high-risk patients for mbe can help clinicians make appropriate triage and early intervention decisions, potentially saving patients' lives. predictive factors for post-ischemic stroke brain edema have been widely discussed, and reliable early predictive indicators have been identified, such as age, early consciousness disorders, baseline national institutes of health stroke scale (nihss), atrial fibrillation, hypertension, baseline blood glucose, and the level of reperfusion after evt. radiological factors, such as the alberta stroke program early ct score (aspects), collateral circulation rating of arteries, venous outflow status, ct perfusion core infarct volume, perfusion-based collateral status, and clot burden, are closely associated with the occurrence of mbe post-evt. however, due to individual differences and multiple factors affecting mbe, a single factor cannot effectively predict mbe. establishing a clinical risk prediction model can effectively identify high-risk populations for mbe at an early stage.

Eligibility criteria:
inclusion criteria: * (1)age \> 18 years old; (2)onset of stroke to hospital admission \< 24 hours; (3)admission with a head ct scan ruling out hemorrhage; (4)patients undergoing ct perfusion scan before treatment; (5)confirmation of internal carotid artery (ica) or middle cerebral artery (mca) occlusion or tandem occlusion by digital subtraction angiography (dsa) and subsequent evt; (6)complete 3-months follow-up. exclusion criteria: * (1)poor quality of preoperative ct perfusion imaging; (2)posterior circulation occlusion or isolated anterior cerebral artery occlusion; (3)presence of other severe diseases such as malignant tumors, severe organ failure, or other life-threatening conditions with an expected survival period of less than 90 days; (4)incomplete imaging and clinical data.

Keywords: endovascular therapy brain edema prediction model ischemic stroke
a prolongation of a clinical study to evaluate the efficacy of an aqueous gel containing 2% (w/w) of cidofovir, directly applied on the cervix exhibiting high grade squamous intraepithelial lesions.

Conditions: High Grade Cervical Epithelial Neoplasia (CIN2+)

Summary: the infections of high grade induced by the human papilloma viruses cause precancerous lesions of the cervical epithelium. the progression of these lesions can lead to the onset of cervical cancer. to reduce the risk of cancer lesions classified as 'cervical squamous intraepithelial neoplasia 2' (cin2) and 'cervical squamous intraepithelial neoplasia 3' (cin3), the standard treatment is the conisation of the cervix. this surgery can lead to complications such as infertility or a risk of preterm birth, hence the need to move towards a non-surgical alternative therapy. the colvir clinical trial was a phase-ii, multi center, randomized, double blind, efficacy study of an aqueous gel containing 2% (w/w) cidofovir, administrated directly on cervix exhibiting high grade squamous intraepithelial lesion (cin 2 and 3). this clinical trial is a prolongation of the colvir trial, in order to * assess the long term histological and virological evolution (24 months) of 3 g of 2% (w/w) cidofovir gel, administrated directly on cervix exhibiting high grade intraepithelial neoplasia after complete response, partial response or response failure at the end of the colvir study. * assess the long term (24 months) rate of recurrence of histological lesions of the colvir patients after conisation, in both placebo and treatment groups.


Eligibility criteria:
inclusion criteria: * women who participated in the colvir study and received complete treatment exclusion criteria: * women from the colvir study who received incomplete treatment

Keywords: colvir high grade squamous intraepithelial lesions cervix
the effectiveness of eldecalcitol in the bisphosphonate non-respondered-patients with osteoporosis

Conditions: Osteoporosis

Summary: in the patients with osteoporosis, bisphosphonates (bps) are a golden standard treatment. however, the bone turnover markers or the bone mineral density (bmd) are not improved in some osteoporotic patients even though they have taken bps and alfacalcidol more than several years. in those case, the investigators better off prescribing bps and eldecalcitol, instead of bps and alfacalcitol.

alfacalcitol and eldecalcitol are the similar vitamin d drugs. however, eldecalcitol is an improved vitamin d drug than alfacalcitol. therefore, we investigate the effectiveness of eldecalcitol in this study.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of osteoporosis * must be able to swallow tablets exclusion criteria: * n/a

Keywords: the changes of bone mineral density and bone turnover markers
effect of two different doses of neostigmine on the gastric residual volume and aspiration in critically ill patients

Conditions: Gastric Reflux

Summary: a study comparing the effect of two doses of neostigmine on the gastric residual volume in critically ill patients on enteral feeding.

participants were categorized into three groups: group i and group ii received neostigmine 1 mg and 2 mg, respectively, and a control group received 10 ml of normal saline. all participants received an intravenous administration of 10 mg of metoclopramide. grv was measured every 3 hours before enteral feeding. aspiration through nasogastric (ng) or orogastric (og) tubes was done before the next due bolus of feeding.

Eligibility criteria:
inclusion criteria: * patients with a grv \>120ml * a normal heart rateexclusion criteria * absence of comorbidities such as diabetes and renal failure. exclusion criteria: * patients exhibiting new-onset arrhythmias or heart block * hypotension (systolic blood pressure less than 60 mmhg) * experiencing active gastrointestinal bleeding or receiving prokinetic medications 8-12 hours before the intervention * patients with a history of surgery in the gastrointestinal system in the past two weeks history of extrapyramidal manifestations * patients with electrolyte imbalance * pregnant patients,
galvus (vildagliptin) vs placebo in combination with metformin and insulin

Conditions: Type 2 Diabetes

Summary: the main objective is to show that the addition of galvus versus placebo in patients with type 2 diabetes treated with metformin (at the maximum tolerated dose) and basal insulin properly titrated, allows a greater proportion of patients achieving an hba1c below 7%. the primary efficacy endpoint was the percentage of patients responding to treatment (hba1c less than 7%) after 3 months of treatment with galvus or placebo

* visit v1 : screening * inclusion visit v2: be verified inclusion criteria of patient. at the inclusion visit will be collected: * informed consent to participate in the study... * the following data: age, duration of diabetes, usual basal insulin dose, other co-morbidities : hypertension, complications of diabetes, dyslipidemia, smoking (and their associated treatments). * data from physical examination and in particular: weight, bmi, waist circumference, systolic blood pressure (sbp) and diastolic (dbp) * therapeutic adjustments can be made. in the case of inefficient combination with a sulphonylurea (hba1c\> 7%), it will be stopped and basal insulin will be titrated during the run- in period (2 months) in order to obtain a good control of fasting glucose. * visit v3 : at the randomization visit, be collected the results of hba1c and other biological assessment (fpg, fasting lipid profile). moreover, the insulin will be collected and the patient will receive the treatment for 3 months (for ex galvus in this case according to randomisation). * visit v4a the glycemic holter will be introduced and removed 5 days later (at visit v4b). the interstitial glucose will be calibrated during the holter by the blood glucose. when collecting the glycemic holter, patients will also have a clinical examination and a new biological assessment (hba1c, fpg, c peptide, fasting lipids ...) and an assessment of their dietary intake during the port the holter (overall calorie intake: cal + g, l, p) * visit v5 : the patient will receive the treatment for 3 months (placebo at this visit according the example cited above ). * visit v6a, it will be the same as for the visit v4a, the glycemic holter will be introduced and removed at v6b visit. similarly, in the collection of glycemic holter, patients will also have a new clinical examination, laboratory evaluation (hba1c, fpg, fasting lipids ...) and a dietary assessment (overall calorie intake: cal + g, l, p).

Eligibility criteria:
inclusion criteria: * patients treated for at least 3 months with metformin (at the maximum tolerated dose (for at least 1 month) + / - sulfamide and basal insulin * patient with an hba1c between 7 and 9% at the inclusion visit * patients able to use a continuous glucose monitoring system, exclusion criteria: * patients already receiving a specific treatment of postprandial (glp1, ..) * patients with type 1 diabetes, or secondary diabetes * patients with eating disorders * patients with major complications of diabetes * patients participating in another clinical trial * pregnant

Keywords: type 2 diabetes galvus basal insulin hba1c
family influences to prevent childhood obesity

Conditions: Childhood Obesity

Summary: the main goal of this project is to develop, deliver, and assess the efficacy of a parent-centered educational program (4-health) designed to prevent preteen children from becoming overweight.

previous studies suggest that parents can play a key role in preventing childhood obesity. program objectives are to increase parents' knowledge and skills related to nutrition, physical activity, and best parenting practices. developed from a successful existing program, the proposed program will include a novel classroom curriculum coupled with outside exercises, online resources, and a strong social support network. the curriculum will be developed with input from stakeholders during year 1 and implemented during years 2 and 3. the target groups are children and parents participating in 4-h youth development programs in montana. intervention effectiveness will be assessed by comparing objective and self-report data between-groups (intervention vs. control) and within-groups (pre- to post-intervention and at 6 month follow-up). physiological measures, including resting heart rate, blood pressure, body weight and age- and gender-specific bmi z-scores of children, are expected to show significant improvement among children of parents receiving the intervention compared to a mailed written materials control group. in addition, positive changes are anticipated in outcome measures provided by parents and children, including levels of daily physical activity and specific food and nutrition behaviors. positive changes in parents' attitudes about diet, body image, and their perceived feeding practices before versus after intervention and at 6 month follow-up are also expected. this project will lead to improved understanding of how parents influence child obesity and improved interventions to prevent obesity.

Eligibility criteria:
inclusion criteria: * parent of 8-12 year old child in 4-h youth development programs in montana * child of parent enrolled in study exclusion criteria: * parent of child age outside the 8-12 year old range at start of trial

Keywords: obesity prevention preteen nutrition physical activity body image family dynamics
a clinical trial of the study medicine (called fosmanogepix) in participants with varying degrees of hepatic function.

Conditions: Hepatic Impairment

Summary: the primary purpose of this open-label study is to characterize the plasma pharmacokinetics (pk) of manogepix (active moiety of fosmanogepix) in participants with varying degrees of hepatic function following administration of a single oral dose of fosmanogepix. all participants will receive 1 dose of fosmanogepix by mouth before breakfast on the first day at the study clinic. serial blood samples will be collected to understand how fosmanogepix is changed and eliminated from the body. participants will also receive physical examination and other tests. this will help to understand if fosmanogepix is safe. participants will be involved in this study for 4 to 9 weeks (maximum). there will be 2 to 4 study visits at the study clinic.


Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 17.5 to 40.0 kg/m2 (42 kg/m2 for participants of cohort 3), inclusive; and a total body weight greater than 50 kg (greater than 110 lb) * for participants with hepatic impairment (cohorts 1-3): stable hepatic impairment that meets the criteria for class a, b, or c of the child pugh classification with no clinically significant change in disease status within the 28 days prior to the screening visit * for participants with normal hepatic function (cohort 4): no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ecg and clinical laboratory tests * stable concomitant medications for the management of individual participants' medical history key exclusion criteria: * any condition possibly affecting drug absorption (eg, prior bariatric surgery, gastrectomy, ileal resection); * ongoing medical history of neurological disorders including abnormal movements or seizures (note exception: stable history of peripheral neuropathy); * hepatic carcinoma or hepatorenal syndrome or limited predicted life expectancy; * a diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, physical examination, liver biopsy, hepatic ultrasound, computerized tomography scan, or mri; * signs of clinically active grade 2, 3 or 4 hepatic encephalopathy (ie, equal or greater than grade 2 portal systemic encephalopathy score)

Keywords: fosmanogepix manogepix hepatic impairment pf-07842805 apx001 apx001a
therapeutic schools: affect management and hiv prevention

Conditions: HIV Infections

Summary: adolescents are at risk for hiv because of sexual and drug behavior intiated during this developmental period. those with psychological distress are less likely than their peers to benefit from frequently used skills-based interventions. it appears that emotional lability during sexual situations disrupts skills learned. this project will implement and evaluate interventions for adolescents with psychiatric disorders who are in therapeutic school settings. affect management and skills-based interventions will be compared to a didactic standard of care condition to determine which intervention best reduces risk behavior among adolescents with psychiatric disorders in therapeutic school settings.


Eligibility criteria:
inclusion criteria: * adolescent attending therapeutic school exclusion criteria: * adolescent is hiv positive * adolescent is developmentally delayed * adolescent is pregnant * adolescent has a history of sexual crime

Keywords: hiv prevention hiv seronegativity
the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach

Conditions: Prostatectomy; Prostate Neoplasm

Summary: the goal of this observational study was to compare the perioperative outcomes, postoperative urinary control rates and positive surgical margin (psm) rates of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach (ap-rarp) with the retzius-sparing approach (rs-rarp) and anterior approach (anterior-rarp) in the treatment of prostate cancer. the main question it aims to answer was: • the early therapeutic efficacy of the robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach participants has been underwent: * ap-rarp * rs-rarp * anterior-rarp researchers compared the three groups to see if ap-rarp combines the advantages of anterior and posterior rarp and is a feasible surgical option for the treatment of prostate cancer.


Eligibility criteria:
inclusion criteria: * pathologically diagnosed with prostate cancer by prostate biopsy * underwent robot-assisted laparoscopic surgery * the surgery performed by weidong gan * the extended pelvic lymphadenectomy (pla) is performed on patients with high-risk prostate cancer (psa≥20 ng/ml or grade group 4-5 or clinical stage ≥t2c) and those considered to have a possibility of lymph node metastasis based on imaging evaluation. exclusion criteria: * patients with a clinical and pathological tnm stage ≥t3b and n1 * patients with distant metastasis * urinary incontinence before surgery * received neoadjuvant therapy before surgery
compare electrodry needlig and dry needling in mechanical low back pain

Conditions: Quadratus Lumborum Syndrome

Summary: mechanical low back pain (lbp) generally results from an acute traumatic event, but it may also be caused by cumulative trauma. the severity of an acute traumatic event varies widely, from twisting one's back to being involved in a motor vehicle collision. mechanical lbp due to cumulative trauma tends to occur more commonly in the workplace and quadratus lumborum injury plays an important role in causing mlbp. the aim of this study is to compare the effects of electrical dry needling and dry needling on pain, endurance and range of motion in patients with quadratus lumborum syndrome.

a randomized clinical trial will be conducted at ali afzal shah dispensary and inam ul haq clinic lahore through consecutive sampling technique on 40 patients which will be allocated using simple random sampling and patients will be divided in group a and b. group a will receive electrical dry needling along with conventional physiotherapy. the parameters for electro dry needling will be needles of 30×0.25 mm, 50×0.25 mm sizes frequency 80-100 hz, duration 10-30 minutes and intensity as tolerated 1 session per week along with 5 day conventional physiotherapy a week for 4 weeks. group 2 will receive dry needling along with conventional physiotherapy in which parameters will be dry needles will be 30×0.25 and 50×0.25 mm sizes once per week and 5 days of conventional physiotherapy per week for 4 weeks. data will be analyzed during spss software version 25. after assessing normality of data by shapiro-wilk test, it will be decided either parametric or non-parametric test will be used within a group or between two groups.

Eligibility criteria:
inclusion criteria: * age 25 to 45 years. * male and females both included. * muscle hypersensitivity on palpation * deep aching pain in sides of the lower back. * positive side-bridge test (right \< 83.2 sec and left \< 81.5 sec) * positive simon's criteria for quadratus lumborum * patients with nprs \<7 * odi score of \< 40 * decreased lumber side flexion and extension rom * positive apperent leg length discrepancy with more than 2 cm * negative laslet's criteria for sacroiliac dysfunction exclusion criteria: * people with real leg length discrepancy * people with any other medical condition including lumbar fracture, spondylolisthesis, ankylosing spondylysis, rheumatoid arthritis. all these conditions will be ruled out with carefully history and examination. * people taking any other form of treatment including corticosteroids, non-steroidal anti-inflammatory drugs or analgesics. * people with previous history of surgical treatment for lumbar spine. o people with neurological deficits or systemic illness

Keywords: dry needling endurance pain range of motion quadratus lumborum syndrome